Publications by authors named "Mitsuhiro Mori"

Claim this Profile
O
One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial.
Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P Schuring, Mitsuhiro Mori

Vaccine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P Schuring, Mitsuhiro Mori

Vaccine· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P Schuring, Mitsuhiro Mori

Vaccine· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Kenji Kuriyama, Kyoko Murakami, Taisei Masuda, Kenkichi Sugiura, Sho Sakui, Mitsuhiro Mori

Vaccine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
Taisei Masuda, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P Schuring, Mitsuhiro Mori

Vaccine· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Taisei Masuda, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron Philip Schuring, Mitsuhiro Mori

Vaccine· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines.
Michael Karbiener, Maria R Farcet, Andreas Zollner, Taisei Masuda, Mitsuhiro Mori

NPJ Vaccines· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide].
Keiji Kusumoto, Mitsuhiro Mori, Junichi Tanokashira, Nobuo Totsuka

Nihon Yakurigaku Zasshi· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis